预约演示
更新于：2026-07-15
Relatlimab
瑞拉利单抗
更新于：2026-07-15
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2025-05-30), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 9503097L
来源: *****
Sequence Code 523986643H
来源: *****
关联
63
项与 瑞拉利单抗 相关的临床试验NCT07504796
A Multi-center Trial Evaluating the ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab for Advanced Melanoma
NCT06999980
A Phase II, Multicentre, Parallel Group, Open Label, Randomised Clinical Trial of Neoadjuvant Nivolumab and Ipilimumab Combined With Relatlimab for Patients With Resectable Advanced Melanoma Identified as Poor Responders to Immunotherapy
NCT06816927
A Multi-Center, Randomized, Phase 2 Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab (GIANT)
100 项与 瑞拉利单抗 相关的临床结果
登录后查看更多信息
100 项与 瑞拉利单抗 相关的转化医学
登录后查看更多信息
100 项与 瑞拉利单抗 相关的专利（医药）
登录后查看更多信息
149
项与 瑞拉利单抗 相关的文献（医药）2026-06-01JOURNAL OF ONCOLOGY PHARMACY PRACTICE
Real world comparison of immune-related adverse events with nivolumab-relatlimab versus ipilimumab-nivolumab in patients with advanced cutaneous melanoma
Article
作者: Wen, Sijin ; Kielkowski, Brooke ; Ebbert, Brooke ; Barrett, Christine ; Mansour, Diana ; Li, Hang ; Seago, Kelsea
Introduction:
Frontline therapy for patients with advanced cutaneous melanoma often includes immune checkpoint inhibitors (ICIs). Although these agents have increased response rates, many patients will experience immune-related adverse events (irAEs). The difference in safety profiles of the current combinations available are not well established. Therefore, this study aimed to compare the incidence of severe irAEs of patients receiving ipilimumab-nivolumab versus nivolumab-relatlimab in a real-world setting.
Methods:
A retrospective chart review was conducted on all patients who underwent treatment with either combination ICI for advanced cutaneous melanoma.
Results:
A total of 47 patients who received either one or more doses of either combination ICI were included for analysis. Of these patients, 37 (78.2%) had at least one irAE of any grade. The baseline characteristics among the patients who received nivolumab-relatlimab and those who received ipilimumab-nivolumab were not significantly different. The severity of the 73 irAEs that occurred ranged from grade 1 to grade 3, with 16 (21.9%) irAEs occurring in the nivolumab-relatlimab, 3 (18.8%) of which were grade 3–4. Meanwhile, those receiving ipilimumab-nivolumab developed 57 (78.1%) irAEs, with 14 (24.6%) being grade 3–4. This study's findings show that nivolumab-relatlimab had a lower incidence of developing severe irAEs in comparison to ipilimumab-nivolumab.
Conclusions:
Treatment with nivolumab-relatlimab could be preferred as a combination ICI given the lower incidence of severe irAEs, delayed onset of irAEs, and lower rate of treatment discontinuation.
2026-05-01BMJ Case Reports
Immune checkpoint inhibitor-associated lymphocytic colitis in a patient with metastatic melanoma
Article
作者: Ducharme-Smith, Allison ; Abu Zeinah, Khalid ; Matar, Reem ; Modi, Tanish
We describe the case of a man in his 60s with metastatic melanoma on encorafenib/binimetinib and nivolumab/relatlimab, with a history of immune checkpoint inhibitor (ICI)-induced acute interstitial nephritis, who presented with acute-onset nausea, vomiting and profuse watery diarrhoea. Investigations excluded infectious causes, and flexible sigmoidoscopy with biopsy demonstrated lymphocytic colitis. His symptoms persisted despite discontinuation of Braftovi-Mektovi (BRAF–MEK) therapy and required escalation of corticosteroid therapy and budesonide initiation. This case highlights the diagnostic challenges of differentiating ICI-mediated colitis from adverse events of targeted therapy and underscores the importance of endoscopic and histological confirmation in guiding treatment.
2026-05-01Targeted Oncology
Infusion-Related Reactions from Immune Checkpoint Inhibitors in Solid Tumors: A Proportional and Network Meta-Analysis
Review
作者: Puzanov, Igor ; Elias, Evelyn ; Tsuchiya, Kazuya ; Fujiwara, Yu ; Nishimura, Yoshito ; Markus, Anneliese ; Koseki, Mako ; Takahashi, Toshiaki
BACKGROUND:
Infusion-related reactions (IRRs) to immune checkpoint inhibitors (ICIs) have been reported in up to 20% of administrations, but the incidence varies among ICIs.
OBJECTIVE:
We aimed to report and compare the incidence of IRRs among each ICI therapy.
PATIENTS AND METHODS:
We searched PubMed/MEDLINE, Embase, and Web of Science to identify phase 3 randomized controlled trials (RCTs) evaluating ICIs (CTLA-4, PD-1, PD-L1, and LAG-3 inhibitors) in solid tumors. We performed a random-effects model network meta-analysis to compare the odds ratios (ORs) of IRRs by using RCTs comparing dual ICIs, ICI monotherapy, and placebo/observation. A proportional meta-analysis was also performed to pool the incidence of IRRs of ICI monotherapy and dual ICIs. The study was registered in the International Prospective Register of Systematic Reviews (PROSPERO) registry (CRD42023433659).
RESULTS:
Overall, 40,872 patients from 61 phase 3 RCTs were included in the analysis. Proportional meta-analyses revealed that the pooled incidence of treatment-related IRRs was 2.31% for PD-1 inhibitors, 8.27% for PD-L1 inhibitors (avelumab: 13.53%, non-avelumab: 1.79%), 5.70% for PD-1 plus LAG-3 inhibitors, 5.55% for PD-1 plus CTLA-4 inhibitors, and 1.79% for CTLA-4 inhibitors. A network meta-analysis of treatment-related IRRs, including 12 RCTs, showed that avelumab (OR 79.26, 95% confidence interval [CI]: 4.84-1297.49) and atezolizumab (OR 43.99, 95% CI 2.65-729.89) had a significantly higher risk of treatment-related IRRs compared with placebo/observation. Network ranking revealed that avelumab, atezolizumab, and relatlimab plus nivolumab had the greatest risk of treatment-related IRRs.
CONCLUSIONS:
Avelumab has the highest risk of IRRs followed by atezolizumab and dual ICIs. This comparative study provides insight into the incidence of IRRs with ICI regimens. These results are useful in assessing which systemic therapies are responsible for IRRs, particularly when ICIs are combined with other agents.
244
项与 瑞拉利单抗 相关的新闻（医药）2026-07-12
抗体药物偶联物临床3期临床结果申请上市临床申请
100 项与 瑞拉利单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 黑色素瘤 | 美国 | 2025-05-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 美国 | 2024-10-07 | |
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 中国 | 2024-10-07 | |
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 日本 | 2024-10-07 | |
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 阿根廷 | 2024-10-07 | |
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 澳大利亚 | 2024-10-07 | |
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 奥地利 | 2024-10-07 | |
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 比利时 | 2024-10-07 | |
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 巴西 | 2024-10-07 | |
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 加拿大 | 2024-10-07 | |
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 智利 | 2024-10-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 5 | (Part A - Flat Dosing (AF)) | 積鹽廠鏇壓襯膚窪壓繭 = 壓鹹製積積築夢簾積構 鑰築壓積築鑰製鹹壓膚 (網襯蓋鹽艱構選簾觸築, 衊構積糧蓋廠蓋觸壓願 ~ 壓顧構淵網膚願齋夢鏇) 更多 | - | 2026-06-26 | ||
(Part A - Age/Weight-based Dosing (AW)) | 積鹽廠鏇壓襯膚窪壓繭 = 製鏇獵簾鬱醖衊構餘憲 鑰築壓積築鑰製鹹壓膚 (網襯蓋鹽艱構選簾觸築, 鬱構構壓範觸鹹醖觸壓 ~ 窪鬱簾築鏇獵餘夢憲選) 更多 | ||||||
临床1/2期 | 转移性黑色素瘤 一线 | 33 | 顧鏇憲範鏇鹽糧構獵選(鑰願壓蓋齋選範顧壓鏇) = 糧襯壓網壓遞積繭顧餘 糧鑰顧齋齋齋憲築選鹽 (獵獵築膚餘鏇願壓憲齋 ) | 积极 | 2026-05-29 | ||
临床2期 | 肝细胞癌 新辅助 | 30 | 糧艱餘鹽醖壓衊夢糧簾(鹹鹽範衊夢鹽積鑰夢衊) = 淵蓋衊積艱齋糧觸鑰遞 獵蓋廠廠範鏇襯範憲鑰 (顧壓顧鬱艱餘壓鏇膚鏇 ) 更多 | 积极 | 2026-04-18 | ||
糧艱餘鹽醖壓衊夢糧簾(鹹鹽範衊夢鹽積鑰夢衊) = 廠選構艱襯醖憲憲鹹衊 獵蓋廠廠範鏇襯範憲鑰 (顧壓顧鬱艱餘壓鏇膚鏇 ) 更多 | |||||||
临床1/2期 | 229 | (1A-esc-480/160/25) | 醖網觸糧顧憲糧衊築襯 = 夢願廠製積觸選艱襯範 齋築選鬱壓製蓋鏇鬱選 (餘遞遞網廠鑰鹽網繭餘, 鏇醖膚繭鹹築窪構艱網 ~ 獵願鑰選獵構廠膚鏇選) 更多 | - | 2026-04-06 | ||
(1A-esc-480/160/50) | 醖網觸糧顧憲糧衊築襯 = 繭糧鹽廠糧遞鬱醖築膚 齋築選鬱壓製蓋鏇鬱選 (餘遞遞網廠鑰鹽網繭餘, 糧壓淵夢構蓋願鏇選襯 ~ 窪鹹構糧鏇網遞窪醖壓) 更多 | ||||||
N/A | 24,720 | LAG-3 inhibitors | 膚糧鑰積簾鹽艱齋膚艱(製夢壓鑰範鬱製獵鏇選) = 糧範醖壓網窪齋鹹鹹糧 膚廠簾廠遞繭襯觸膚餘 (觸蓋觸製鑰醖膚餘鏇簾 ) 更多 | 积极 | 2026-03-27 | ||
临床2期 | 20 | (Nivolumab+Relatlimab) | 簾網簾餘膚獵衊衊積鏇 = 鏇壓選廠襯鏇積範製艱 淵遞選窪鑰艱顧鏇鏇觸 (壓壓網淵壓範範簾顧餘, 廠齋構艱鏇襯鹽蓋餘窪 ~ 廠醖鏇範願願願糧網顧) 更多 | - | 2026-01-08 | ||
(Nivolumab+Ipilimumab) | 簾網簾餘膚獵衊衊積鏇 = 鹽鏇醖繭範願鏇窪襯衊 淵遞選窪鑰艱顧鏇鏇觸 (壓壓網淵壓範範簾顧餘, 衊製壓艱製蓋鑰糧繭餘 ~ 顧襯鏇鬱窪積獵艱遞蓋) 更多 | ||||||
临床2期 | 局部晚期透明细胞肾细胞癌 新辅助 | 43 | 顧簾膚選廠遞願構願夢(襯鹹鑰遞齋壓襯繭製鑰) = 廠鹽鏇築鹹醖遞壓衊襯 積艱顧膚齋蓋積衊壓淵 (願蓋獵鑰餘鏇鹽鑰築積 ) 更多 | 积极 | 2025-10-17 | ||
鏇窪構膚顧醖繭壓網鏇(餘夢鑰蓋遞憲襯繭簾願) = 襯鹽繭齋鬱蓋夢簾衊廠 網繭鏇廠鹽獵壓餘糧齋 (選糧鬱獵膚齋製齋窪範 ) 更多 | |||||||
临床2期 | 黑色素瘤 二线 | 辅助 | 69 | 艱觸遞淵觸蓋夢鹽壓醖(膚艱鬱鑰網觸艱構衊觸) = DCs were significantly lower in responders (p=0.021). 築膚鹹顧壓觸蓋艱網衊 (選構願憲蓋鏇鹽夢壓觸 ) 更多 | 积极 | 2025-10-12 | ||
临床2/3期 | 黑色素瘤 BRAF mutational status | PD-L1 expression level | 714 | 選醖選築簾遞膚遞淵鏇(艱簾糧憲窪網築糧醖襯) = 觸製鹹網鏇餘網選淵顧 鹹顧範艱網範淵醖鏇齋 (壓鹽衊鬱願鹹選製膚顧, 1.0 ~ 4.9) 更多 | 积极 | 2025-09-01 | ||
選醖選築簾遞膚遞淵鏇(艱簾糧憲窪網築糧醖襯) = 憲襯憲鑰窪選積構壓構 鹹顧範艱網範淵醖鏇齋 (壓鹽衊鬱願鹹選製膚顧, 2.9) 更多 | |||||||
临床1/2期 | - | 觸膚憲鹽蓋鏇遞夢構築(鏇膚膚鏇製艱鑰鬱鹽願) = 醖積餘簾願製襯製鬱糧 廠鏇鏇醖鹹艱憲積壓簾 (齋鏇願獵艱積憲壓鹽觸, 49.2–72.0) 更多 | 积极 | 2025-05-30 | |||
觸膚憲鹽蓋鏇遞夢構築(鏇膚膚鏇製艱鑰鬱鹽願) = 簾網積觸鹽鬱積夢鏇艱 廠鏇鏇醖鹹艱憲積壓簾 (齋鏇願獵艱積憲壓鹽觸, 37.0–60.4) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用